ZEPHYRx
ZEPHYRx is a digital health SaaS platform combining FDA-cleared Bluetooth spirometers, a patient mobile app, and a cloud provider dashboard with AI spirometry overreading. It serves healthcare providers managing chronic respiratory patients and clinical research organizations running decentralized respiratory trials.
- Company typePrivate
- Founded2019
- HeadquartersTroy, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What ZEPHYRx does
ZEPHYRx is a digital health SaaS company providing cloud-based remote respiratory monitoring (RRM) for two primary customer segments: healthcare providers managing patients with chronic respiratory conditions (COPD, cystic fibrosis, pulmonary fibrosis, asthma, and related indications), and clinical research organizations, sponsors, and academic investigators running decentralized and hybrid respiratory clinical trials. Founded in 2019 and headquartered in Troy, New York, the company operates as ZEPHYRx LLC (Delaware-domiciled), is a subsidiary of My Music Machines Inc., and is majority-owned by Chairperson Sue Whalen with no institutional venture or growth-equity capital disclosed. The company originated from an NIH/NHLBI-funded STTR grant awarded to cofounder Michael DiCesare to develop a respiratory therapy device using interactive gaming and music, and gained initial traction during the COVID-19 pandemic by distributing connected spirometers for at-home pulmonary function testing to top US hospitals.
The ZEPHYRx platform is a three-layer architecture: a patient-facing Breathe Easy mobile app (iOS, Android, and Amazon), FDA-cleared Bluetooth-enabled MIR Spirobank spirometers (single-patient home and multi-patient point-of-care kiosk variants), and a cloud-based Provider Dashboard that delivers real-time video coaching, AI-driven spirometry overreading against ATS/ERS 2019 standards, custom surveys, compliance monitoring, and automated alerts. The platform captures spirometry endpoints (FVC, FEV1, SVC, Peak Flow), FeNO via NIOX integration, and ePRO/eCOA, and is HIPAA, GDPR, CCPA, and SOC 2 compliant. Trial-side modules include Kiosk for point-of-care testing, Home for at-home monitoring, and a Gateway API integration layer; healthcare-side modules include EMR integration and SSO connectors. Strategic integrations extend the platform to Morgan Scientific (ComPAS2), RxCap, ActiGraph wearables, and the Target ALS Data Engine.
ZEPHYRx monetizes through a per-patient-per-month subscription for healthcare providers (which only bills when a test is performed), hardware resale of MIR spirometers (ZEPHYRx is MIR's largest reseller), and clinical research services including trial setup, project management, global logistics, and data management. Distribution is hybrid: direct enterprise field sales, an exclusive North American channel partnership with MIR, CRO and RPM partner programs for white-label and indirect distribution, and self-serve patient app distribution through app stores. To date the company has delivered more than 40,000 spirometers, supported 50+ clinical studies covering CF, ALS, COPD, asthma, IPF, ILD, and other respiratory indications, and monitored 10,000+ research participants remotely.
ZEPHYRx firmographics
Firmographics- Name
- ZEPHYRx
- Legal name
- ZEPHYRx LLC
- Website
- https://zephyrx.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ZEPHYRx is a digital health SaaS platform combining FDA-cleared Bluetooth spirometers, a patient mobile app, and a cloud provider dashboard with AI spirometry overreading. It serves healthcare providers managing chronic respiratory patients and clinical research organizations running decentralized respiratory trials.
- Ownership category
- akta.pro rank
ZEPHYRx industry classification
Industry- Product category
- Remote Respiratory Monitoring (Digital Health SaaS)
- NAICS
- Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Respiratory & Sleep RPM (COPD, asthma, sleep apnea) (HLALAFAB)
- akta.pro secondary industries
- Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate) (HLAHAGAI), Chronic Disease Remote Monitoring (COPD/CHF/HTN, Weight & Symptom Tracking) (HLAHACAI)
Keywords
Where ZEPHYRx is headquartered
LocationHeadquarters
- HQ city
- Troy
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
ZEPHYRx business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Subscription - Remote Respiratory Monitoring: Subscription-based model for cloud platform access and remote respiratory monitoring services. Subscribers pay a flat rate per patient per month with testing-inclusive pricing - if no test is performed, no charge; multiple tests still incur only the flat rate. Includes reimbursement support services, patient onboarding, and technical support.
- Spirometer Hardware Sales: Sales of MIR Spirobank Smart and Spirobank II Smart BLE FDA-cleared spirometers. ZEPHYRx is the largest reseller of MIR spirometers. Spirometers are sold to healthcare practices and clinical research organizations for at-home and point-of-care use.
- Clinical Research Services: Comprehensive services for decentralized and hybrid clinical trials including trial setup and kickoff, project management, data management, global logistics, 24/7 support, and compliance with GCP standards.
- RPM Reimbursement Support: Reimbursement services included in subscription to help providers navigate home spirometry reimbursement challenges with ongoing support and documentation for CPT code submissions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Subscription - Cost-Effective RRM Solution |
Go-to-market motion4 records
Distribution channels5 records
Marketing channels7 records
ZEPHYRx product offering
Product offeringCore offering
ZEPHYRx provides a cloud-based Remote Respiratory Monitoring (RRM) platform that combines FDA-cleared Bluetooth spirometers, a free patient-facing Breathe Easy mobile app, and a web-based Provider Dashboard. It enables healthcare providers and decentralized clinical trials to capture pulmonary function data (FVC, FEV1, SVC, Peak Flow, FeNO, ePRO) remotely with real-time video coaching, AI spirometry overreading, automated alerts, and integrated reimbursement support.
Product overview
ZEPHYRx offers a modular decentralized respiratory monitoring platform comprising three core components: the Breathe Easy patient app (available on iOS, Android, Amazon), the cloud-based Provider Dashboard, and FDA-cleared MIR spirometers (Spirobank Smart for home use, Spirobank II Smart BLE for point-of-care Kiosk). The platform supports two primary testing modalities: Home for remote patient monitoring and Kiosk for point-of-care clinical trials. Gateway enables API-based integration into existing EMR systems and clinical trial platforms. The solution includes real-time video coaching, AI-powered spirometry overreading, gamified breathing exercises, custom surveys/ePROs, and automated alerts. ZEPHYRx also offers CRO Partner Program and RPM Partner Program for channel integration.
Differentiator
Problem solved
Functional benefit
Brands
- Breathe Easy: Free patient-facing mobile application for performing pulmonary function tests, featuring real-time video coaching, PFT notifications, and gamified breathing exercises.
Quantifiable outcome
- Remote spirometry with real-time video coaching provides reliable FEV1 measurement correlating closely with in-person spirometry suitable for clinical trials
- +3 more outcomes
Companies that use ZEPHYRx
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
ZEPHYRx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration7 records
AI capability4 records
Feature9 records
ZEPHYRx partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core, minor and flagship.
- ActiGraphcoreStrategic partnership with ActiGraph, a leading provider of wearable technology and scientific services for clinical drug development and academic research. Enables researchers to combine high-quality wearable behavior data with respiratory function data for comprehensive clinical trial insights.
- Target ALScoreData integration partnership where ZEPHYRx respiratory monitoring data is now available to global scientists via the Target ALS Data Engine. Integrates ZEPHYRx data with rich clinical and biological datasets from Target ALS Global Natural History Study participants for freely accessible ALS research.
- Morgan ScientificcoreStrategic partnership integrating ZEPHYRx's respiratory platform with Morgan Scientific's ComPAS2 PFT software. Enables healthcare providers to monitor patient lung function at-home through an expanded remote spirometry offering powered by ZEPHYRx's respiratory cloud platform.
- NIOXcorePartnership integrating FeNO by NIOX into the ZEPHYRx Respiratory Cloud Platform to offer one source of truth for multiple respiratory endpoints in clinical research. NIOX is the world leader in FeNO testing.
- RxCapcorePartnership integrating ZEPHYRx cloud spirometry platform with RxCap's remote monitoring platform. Enables RxCap's enterprise customers (providers and payers) to monitor lung function of patients with pulmonary conditions through revenue-generating RPM programs integrated with existing care workflows.
- EverythingALScorePartnership in The Radcliff Study, a novel research-as-feasibility study by EverythingALS to develop an end-to-end digital alternative for the ALSFRS-R. ZEPHYRx joins Aural Analytics, FeetMe, and a major pharmaceutical company in this pre-competitive collaboration for ALS research.
- Aural AnalyticsminorCollaboration partner in EverythingALS Radcliff Study focused on developing digital alternatives for ALSFRS-R assessment in ALS research.
- FeetMeminorCollaboration partner in EverythingALS Radcliff Study focused on developing digital alternatives for ALSFRS-R assessment in ALS research.
- MIR (Medical International Research)flagshipExclusive partnership for MIR to jointly market ZEPHYRx Remote Respiratory Monitoring (RRM) Solution in North America. ZEPHYRx is the largest reseller of MIR's Spirobank Smart Spirometer and has been working with MIR since its inception in 2019. MIR leverages its established customer base and sales personnel to accelerate ZEPHYRx's growth.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
ZEPHYRx competitors and assessment
Company assessmentDirect peers
- NuvoAir: NuvoAir provides a digital respiratory care platform combining connected spirometers, mobile apps, and clinician dashboards for COPD and asthma management. It is a direct competitor in remote pulmonary function testing and virtual respiratory care, with overlapping provider and pharma customers.
- Vivify Health: Vivify Health is an RPM platform used by health systems and payers to manage chronic conditions remotely, including respiratory. It competes for the same hospital and payer RPM budgets as ZEPHYRx, and partners with similar device manufacturers for connected peripherals.
- Propeller Health (ResMed): Propeller Health, now part of ResMed, is a direct respiratory RPM competitor offering connected inhalers and a digital platform for asthma and COPD. It targets the same healthcare-provider and pharma-sponsored patient populations as ZEPHYRx and is the most established comparable in the connected-respiratory space.
- Medidata (Dassault Systèmes): Medidata's decentralized trial platform and eCOA/ePRO solutions are used by the same CRO and pharma sponsors ZEPHYRx serves for respiratory clinical trials. It is a direct peer in the decentralized and hybrid respiratory trial endpoint market, though with a much broader modality footprint.
- Castor EDC: Castor is a clinical trial technology platform with eCOA, ePRO, and decentralized trial capabilities used by sponsors and CROs. It is a direct peer in the decentralized respiratory trial space, often evaluated alongside ZEPHYRx for data capture and remote monitoring.
Emerging players
- Strados Labs: Strados Labs provides connected respiratory monitoring (wearable lung sound patches) used in clinical trials and provider care. It is an emerging player in connected respiratory data, and is already a ZEPHYRx partner in the multi-endpoint respiratory trial ecosystem.
- Wellinks: Wellinks offers connected respiratory care for COPD and other chronic lung conditions, with an integrated spirometer, app, and coaching program. It is an emerging player with significant overlap in target patient population and provider use cases for remote pulmonary monitoring.
Others
- RxCap: RxCap is a remote monitoring enablement platform for providers and payers, already integrated with ZEPHYRx for respiratory RPM. It is a partner/complementary platform rather than a direct competitor, competing only at the multi-condition RPM layer above the device-specific data.
Broad incumbents
- Huma (formerly Huma Therapeutics): Huma is a broader digital health and RPM platform used by hospitals, pharma, and CROs across multiple therapeutic areas including respiratory. It is a broad incumbent in the same buyer universe, with comparable regulatory and integration capabilities.
- Biofourmis: Biofourmis is a broader RPM and hospital-at-home platform that increasingly covers respiratory and chronic care use cases. It is a broad incumbent in the same space, with overlapping buyers (health systems, payers, pharma) but a wider therapeutic footprint than ZEPHYRx's respiratory focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
ZEPHYRx social profiles
Digital presenceZEPHYRx compliance and trust
Trust signalCompliance5 records
ZEPHYRx financial estimates
Financial estimateRevenue estimate
Valuation estimate
ZEPHYRx leadership team
Management profileNumber of profiles
Profiles11 records
ZEPHYRx funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ZEPHYRx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ZEPHYRx
What does ZEPHYRx do?
ZEPHYRx provides a cloud-based Remote Respiratory Monitoring (RRM) platform that combines FDA-cleared Bluetooth spirometers, a free patient-facing Breathe Easy mobile app, and a web-based Provider Dashboard. It enables healthcare providers and decentralized clinical trials to capture pulmonary function data (FVC, FEV1, SVC, Peak Flow, FeNO, ePRO) remotely with real-time video coaching, AI spirometry overreading, automated alerts, and integrated reimbursement support.
Is ZEPHYRx a public or private company?
ZEPHYRx is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was ZEPHYRx founded?
ZEPHYRx was founded in 2019. It employs 11 to 50 people.
Where is ZEPHYRx based?
ZEPHYRx is headquartered in Troy, United States, in the North America region.
How does ZEPHYRx make money?
Four revenue lines are on record. Subscription - Remote Respiratory Monitoring is the primary driver. The others are spirometer Hardware Sales, clinical Research Services and RPM Reimbursement Support.
Who are ZEPHYRx's main competitors?
Direct peers on record are NuvoAir, Vivify Health, Propeller Health (ResMed), Medidata (Dassault Systèmes) and Castor EDC. Emerging players are Strados Labs and Wellinks. RxCap is listed as an others. Broad incumbents are Huma (formerly Huma Therapeutics) and Biofourmis.
Does ZEPHYRx have an API?
Yes. ZEPHYRx offers an API for EMR integration, enabling healthcare providers to integrate patient PFT data into their Electronic Medical Records system. The API Guide is described as simple and designed for the provider's IT staff to easily integrate patient data. Additionally, Gateway enables clinical trials to integrate ZEPHYRx respiratory data into their preferred clinical trial management systems or existing remote patient monitoring platforms via API. Developer documentation is at Not specified.
What industry is ZEPHYRx in?
ZEPHYRx's product category is Remote Respiratory Monitoring (Digital Health SaaS). Its primary akta.pro industry code is HLALAFAB, Respiratory & Sleep RPM (COPD, asthma, sleep apnea), with a secondary code of HLAHAGAI, Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate). Its NAICS code is 6215 and its SIC code is 8071.